MXPA05011539A - Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. - Google Patents
Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.Info
- Publication number
- MXPA05011539A MXPA05011539A MXPA05011539A MXPA05011539A MXPA05011539A MX PA05011539 A MXPA05011539 A MX PA05011539A MX PA05011539 A MXPA05011539 A MX PA05011539A MX PA05011539 A MXPA05011539 A MX PA05011539A MX PA05011539 A MXPA05011539 A MX PA05011539A
- Authority
- MX
- Mexico
- Prior art keywords
- protein tyrosine
- compounds
- tyrosine phosphatase
- inhibitors
- carboxylic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La presente invencion se refiere a compuestos y sales farmaceuticamente aceptables de la formula (I), que son utiles en el tratamiento de trastornos metabolicos relacionados a resistencia a insulina, resistencia a leptina o hiperglicemia. Los compuestos de la invencion incluyen inhibidores de las proteinas tirosina-fosfatasas, en particular la proteina tirosina-fosfatasa-1B (PTP-1B), que son utiles en el tratamiento de diabetes y otras enfermedades mediadas por PTP, tal como cancer, enfermedades neurodegenerativas y similares. Tambien se describen composiciones farmaceuticas que comprenden los compuestos de la invencion y metodos para tratar las condiciones mencionadas anteriormente usando estos compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46721403P | 2003-04-30 | 2003-04-30 | |
PCT/US2004/013702 WO2004099192A2 (en) | 2003-04-30 | 2004-04-30 | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05011539A true MXPA05011539A (es) | 2006-01-23 |
Family
ID=33435039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05011539A MXPA05011539A (es) | 2003-04-30 | 2004-04-30 | Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. |
Country Status (8)
Country | Link |
---|---|
US (2) | US7329680B2 (es) |
EP (1) | EP1628970A2 (es) |
JP (1) | JP2006525366A (es) |
AU (1) | AU2004236249A1 (es) |
CA (1) | CA2523743A1 (es) |
MX (1) | MXPA05011539A (es) |
WO (1) | WO2004099192A2 (es) |
ZA (1) | ZA200509634B (es) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004236249A1 (en) | 2003-04-30 | 2004-11-18 | The Institutes Of Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1B |
US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
PT1700856E (pt) * | 2003-12-26 | 2016-02-19 | Kyowa Hakko Kirin Co Ltd | Derivado de tiazole |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
BRPI0511834A (pt) | 2004-07-14 | 2008-01-08 | Ptc Therapeutics Inc | métodos por tratar hepatite c |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
NZ553329A (en) | 2004-07-22 | 2010-09-30 | Ptc Therapeutics Inc | Thienopyridines for treating hepatitis C |
EP1828144A2 (en) | 2004-11-12 | 2007-09-05 | OSI Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
AU2005307718A1 (en) * | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids for the treatment of diabetes |
JP5024039B2 (ja) * | 2005-02-25 | 2012-09-12 | 小野薬品工業株式会社 | インドール化合物およびその用途 |
US20090215857A1 (en) * | 2005-09-13 | 2009-08-27 | Pfizer Products Inc. | Therapeutic Pyrrolidines |
AR056690A1 (es) | 2005-10-14 | 2007-10-17 | Athersys Inc | Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc |
BRPI0708767A2 (pt) | 2006-03-14 | 2011-06-14 | Santen Pharmaceutical Co Ltd | composto, composto ou sal do mesmo, composiÇço farmacÊutica, modulador de receptor de glicocorticàide, e mÉtodo de prevenÇço ou tratamento de uma doenÇa associada a receptor de glicocorticàide |
WO2008072850A1 (en) * | 2006-12-11 | 2008-06-19 | Amorepacific Corporation | Triazine derivatives having inhibitory activity against acetyl-coa carboxylase |
CA2687948A1 (en) | 2007-05-29 | 2008-12-04 | Mamoru Matsuda | Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein andhas glucocorticoid receptor-binding activity |
US8945724B2 (en) * | 2007-12-27 | 2015-02-03 | Idemitsu Kosan Co., Ltd. | Nitrogen-containing heterocyclic derivative and organic electroluminescent device using the same |
US8273744B2 (en) | 2008-02-04 | 2012-09-25 | Mercury Therapeutics, Inc. | AMPK modulators |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
WO2009145286A1 (ja) * | 2008-05-30 | 2009-12-03 | 武田薬品工業株式会社 | 複素環化合物 |
EP2326621B1 (en) | 2008-07-23 | 2016-06-08 | Arena Pharmaceuticals, Inc. | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS |
RS54970B1 (sr) | 2008-08-27 | 2016-11-30 | Arena Pharm Inc | Supstituisani triciklični derivati kiselina kao s1p1 receptor agonisti korisni pri lečenju autoimunih i upalnih poremećaja |
WO2010029986A1 (ja) | 2008-09-12 | 2010-03-18 | 参天製薬株式会社 | スルホン酸エステル構造を導入したフェニル基を置換基として有する新規1,2,3,4-テトラヒドロキノキサリン誘導体からなるグルココルチコイド受容体アゴニスト |
TWI469965B (zh) | 2008-12-22 | 2015-01-21 | Ono Pharmaceutical Co | 乙炔基吲哚化合物 |
EP2414346B1 (en) | 2009-04-02 | 2015-06-24 | Merck Patent GmbH | Autotaxin inhibitors |
EP3378854B1 (en) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
CN103080085B (zh) | 2010-06-21 | 2014-08-13 | 小野药品工业株式会社 | 4,4’-[4-氟-7-({4-[4-(3-氟-2-甲基苯基)丁氧基]苯基}乙炔基)-2-甲基-1h-吲哚-1,3-二基]二丁酸的新晶型 |
EP2508511A1 (en) * | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
SG10201608528YA (en) | 2011-12-21 | 2016-12-29 | Novira Therapeutics Inc | Hepatitis b antiviral agents |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
CA2874953A1 (en) | 2012-06-12 | 2013-12-19 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
CR20200276A (es) | 2012-08-28 | 2021-01-27 | Janssen Sciences Ireland Uc | Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059) |
ES2606197T3 (es) | 2012-11-16 | 2017-03-23 | Bristol-Myers Squibb Company | Moduladores pirrolidina de GPR40 |
US9656963B2 (en) | 2012-11-16 | 2017-05-23 | Bristol-Myers Squibb Company | Dihydropyrazole GPR40 modulators |
AR104762A1 (es) | 2012-11-16 | 2017-08-16 | Bristol Myers Squibb Co | Moduladores de dihidropirazol gpr40 |
JP6466348B2 (ja) | 2013-02-28 | 2019-02-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用 |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
CA2922302C (en) | 2013-04-03 | 2021-08-03 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
CA2935719C (en) | 2013-07-25 | 2021-11-02 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
AP2016009122A0 (en) | 2013-10-23 | 2016-03-31 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9796677B2 (en) | 2013-12-10 | 2017-10-24 | Japan Science And Technology Agency | Amide compound and pharmaceutical comprising same |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
KR20160128305A (ko) | 2014-02-05 | 2016-11-07 | 노비라 테라퓨틱스, 인코포레이티드 | Hbv 감염의 치료를 위한 병용 요법 |
PL3102572T3 (pl) | 2014-02-06 | 2019-04-30 | Janssen Sciences Ireland Uc | Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
WO2016149581A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
LT3307734T (lt) | 2015-06-09 | 2020-05-11 | Abbvie Inc. | Branduolinio receptoriaus moduliatoriai (ror), skirti uždegiminių ir autoimuninių ligų gydymui |
SI3310760T1 (sl) | 2015-06-22 | 2023-02-28 | Arena Pharmaceuticals, Inc. | Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1 |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
AU2016330964B2 (en) | 2015-09-29 | 2021-04-01 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
MA47503A (fr) | 2017-02-16 | 2021-04-21 | Arena Pharm Inc | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
CN106946858A (zh) * | 2017-04-15 | 2017-07-14 | 三峡大学 | 一种三聚氰胺类化合物及其制备方法 |
EA202092171A1 (ru) | 2018-03-14 | 2020-12-01 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Схема дозирования модулятора сборки капсида |
CN108530262A (zh) * | 2018-06-15 | 2018-09-14 | 贾红琴 | 一种2-溴芴的合成方法 |
US11555015B2 (en) | 2018-09-06 | 2023-01-17 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
CU20210042A7 (es) | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
KR20210130753A (ko) | 2019-02-22 | 2021-11-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체 |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
CN113795486A (zh) | 2019-05-06 | 2021-12-14 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
JP2022552735A (ja) | 2019-10-25 | 2022-12-19 | ギリアード サイエンシーズ, インコーポレイテッド | Glp-1r調節化合物 |
WO2022109182A1 (en) | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
KR20230173708A (ko) | 2021-04-21 | 2023-12-27 | 길리애드 사이언시즈, 인코포레이티드 | 카르복시-벤즈이미다졸 glp-1r 조절 화합물 |
GB202108544D0 (en) * | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
CN115337301A (zh) * | 2022-07-22 | 2022-11-15 | 汕头大学医学院第一附属医院 | Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2037630C (en) * | 1990-03-07 | 2001-07-03 | Akira Morimoto | Nitrogen-containing heterocylic compounds, their production and use |
JP3114073B2 (ja) * | 1990-03-07 | 2000-12-04 | 武田薬品工業株式会社 | アンジオテンシンii拮抗薬−含窒素異項環化合物 |
DE4221583A1 (de) * | 1991-11-12 | 1993-05-13 | Bayer Ag | Substituierte biphenylpyridone |
DE4407488A1 (de) * | 1994-03-07 | 1995-09-14 | Bayer Ag | Verwendung von Biphenyl- und Pyridylmethylpyridonen |
US6310081B1 (en) | 1999-05-10 | 2001-10-30 | American Home Products Corporation | Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia |
EP1301516B1 (en) | 2000-07-07 | 2006-03-22 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
AU2001268951A1 (en) | 2000-07-07 | 2002-01-21 | Novo-Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
MXPA01013326A (es) * | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz. |
AU2004236249A1 (en) | 2003-04-30 | 2004-11-18 | The Institutes Of Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1B |
-
2004
- 2004-04-30 AU AU2004236249A patent/AU2004236249A1/en not_active Abandoned
- 2004-04-30 WO PCT/US2004/013702 patent/WO2004099192A2/en active Application Filing
- 2004-04-30 MX MXPA05011539A patent/MXPA05011539A/es not_active Application Discontinuation
- 2004-04-30 US US10/835,818 patent/US7329680B2/en not_active Expired - Fee Related
- 2004-04-30 CA CA002523743A patent/CA2523743A1/en not_active Abandoned
- 2004-04-30 JP JP2006514245A patent/JP2006525366A/ja active Pending
- 2004-04-30 EP EP04751194A patent/EP1628970A2/en not_active Withdrawn
-
2005
- 2005-11-29 ZA ZA200509634A patent/ZA200509634B/en unknown
-
2008
- 2008-02-12 US US12/029,708 patent/US20080146574A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7329680B2 (en) | 2008-02-12 |
WO2004099192A2 (en) | 2004-11-18 |
ZA200509634B (en) | 2008-04-30 |
US20050004114A1 (en) | 2005-01-06 |
US20080146574A1 (en) | 2008-06-19 |
CA2523743A1 (en) | 2004-11-18 |
WO2004099192A3 (en) | 2005-01-13 |
JP2006525366A (ja) | 2006-11-09 |
AU2004236249A1 (en) | 2004-11-18 |
EP1628970A2 (en) | 2006-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05011539A (es) | Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. | |
MXPA05011536A (es) | Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b. | |
RS20050814A (en) | Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b | |
WO2006055708A3 (en) | Heterocycle substituted carboxylic acids for the treatment of diabetes | |
TW200630354A (en) | Substituted amino carboxylic acids | |
MXPA05011523A (es) | Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas. | |
MXPA05010937A (es) | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. | |
MXPA05011524A (es) | Acidos carboxilicos sustituidos. | |
TW200630327A (en) | Substituted phenylalkanoic acids | |
WO2006055625A3 (en) | Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors | |
WO2008033455A3 (en) | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors | |
WO2008033932A3 (en) | Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors | |
WO2008074997A8 (en) | Pyridine benzamides and pyrazine benzamides used as pkd inhibitors | |
WO2004071447A3 (en) | Substituted azole derivatives as therapeutic agents | |
WO2007127474A3 (en) | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | |
WO2007089857A3 (en) | Substituted imidazole derivatives and their use as ptpase inhibitors | |
EA200600414A1 (ru) | ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ) | |
UA96441C2 (ru) | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением | |
WO2004071448A3 (en) | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases | |
WO2007125331A3 (en) | Amino-ethyl-amino-aryl (aeaa) compounds and their use | |
TW200631949A (en) | Substituted carboxylic acids | |
HK1079526A1 (en) | A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin | |
WO2006138589A3 (en) | Opioid receptor ligands | |
ATE442848T1 (de) | Isoxazolsäure-derivat zur linderung neuropathischer schmerzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |